BioCentury | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

...Administration in December for Hodgkin lymphoma. Shenogen has exclusive Chinese rights to SNG1005 (ANG1005) from Angiochem Inc....
BioCentury | Jan 5, 2018
Company News

Angiochem grants Xinogen Chinese rights to ANG1005

...transport into the brain. Xinogen is a subsidiary of Shenogen Pharma Group Ltd. (Beijing, China). Angiochem...
...upfront payment and is eligible for milestones and royalties. Details were not disclosed. This year, Angiochem...
...tumors with brain metastases. Angiochem Inc., Montreal, Quebec Shenogen Pharma Group Ltd., Beijing, China Business: Cancer Mary Romeo ANG1005 Angiochem Inc. Shenogen...
BioCentury | Jan 3, 2018
Company News

Angiochem, Xinogen in China deal

...is a peptide (Angiopep-2) conjugated to three paclitaxel molecules for receptor-mediated transport into the brain. Angiochem...
...not disclosed. Xinogen is a subsidiary of Shenogen Pharma Group Ltd. (Beijing, China). This year, Angiochem...
...carcinomatosis and brain metastases. Shenogen SVP and Chief Business Officer Jun Bao told BioCentury that Angiochem...
BioCentury | Jul 26, 2017
Emerging Company Profile

Breaching the gates

...use receptor-mediated transport to deliver molecules across the BBB, such as 2-BBB Medicines B.V. , Angiochem Inc....
...method for opening tight junctions Companies and Institutions Mentioned 2BBB Medicines B.V., Leiden, the Netherlands Angiochem Inc....
BioCentury | Dec 7, 2015
Clinical News

ANG1005: Interim Phase II data

...generally well tolerated. Data were presented at the Society for Neuro-Oncology meeting in San Antonio. Angiochem...
...Phase III program of ANG1005 to treat breast cancer patients with or without leptomeningeal carcinomatosis. Angiochem Inc....
BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu)

...steps could include testing ANG4043 additional rodent brain tumor models and assessing its safety profile. Angiochem Inc....
...Cancer Ther.; published online Dec. 9, 2014; doi:10.1158/1535-7163.MCT-14-0399 CONTACT: Jean Lachowicz, Angiochem Inc., Montreal, Quebec e-mail: jlachowicz@angiochem.com BC...
BioCentury | Dec 15, 2014
Clinical News

Angiochem preclinical data

...Molecular Cancer Therapeutics. ANG4043 consists of the Angiopep-2 peptide conjugated to an anti- HER2 mAb. Angiochem Inc....
BioCentury | Jun 16, 2014
Regulation

Signal crossing

...It is in Phase I/II testing to treat MPS-VII (Sly syndrome). Companies and Institutions Mentioned Angiochem Inc....
...with iduronidase to treat MPS-I; and AGT-182 , an antibody-fusion with iduronate-2-sulfatase to treat MPS-II. Angiochem Inc....
...LRP1 ( CD91 ), a receptor that ferries biomolecules from the blood to the brain. Angiochem...
BioCentury | Jun 9, 2014
Clinical News

ANG1005: Phase II started

...breast cancer showed that ANG1005 produced no confirmed intracranial responses, the primary endpoint. Last year, Angiochem...
...of stable disease (see BioCentury, Dec. 13, 2010; Dec. 10, 2012 & Oct. 28, 2013). Angiochem Inc....
BioCentury | Mar 13, 2014
Distillery Therapeutics

Indication: Neurology

...delivery of NTS alone or vehicle control. Next steps include IND-enabling studies and clinical testing. Angiochem Inc.'s...
...treat pain. SciBX 7(10); doi:10.1038/scibx.2014.289 Published online March 13, 2014 Angiopep and conjugates patented by Angiochem...
Items per page:
1 - 10 of 57
BioCentury | Aug 6, 2019
Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

...Administration in December for Hodgkin lymphoma. Shenogen has exclusive Chinese rights to SNG1005 (ANG1005) from Angiochem Inc....
BioCentury | Jan 5, 2018
Company News

Angiochem grants Xinogen Chinese rights to ANG1005

...transport into the brain. Xinogen is a subsidiary of Shenogen Pharma Group Ltd. (Beijing, China). Angiochem...
...upfront payment and is eligible for milestones and royalties. Details were not disclosed. This year, Angiochem...
...tumors with brain metastases. Angiochem Inc., Montreal, Quebec Shenogen Pharma Group Ltd., Beijing, China Business: Cancer Mary Romeo ANG1005 Angiochem Inc. Shenogen...
BioCentury | Jan 3, 2018
Company News

Angiochem, Xinogen in China deal

...is a peptide (Angiopep-2) conjugated to three paclitaxel molecules for receptor-mediated transport into the brain. Angiochem...
...not disclosed. Xinogen is a subsidiary of Shenogen Pharma Group Ltd. (Beijing, China). This year, Angiochem...
...carcinomatosis and brain metastases. Shenogen SVP and Chief Business Officer Jun Bao told BioCentury that Angiochem...
BioCentury | Jul 26, 2017
Emerging Company Profile

Breaching the gates

...use receptor-mediated transport to deliver molecules across the BBB, such as 2-BBB Medicines B.V. , Angiochem Inc....
...method for opening tight junctions Companies and Institutions Mentioned 2BBB Medicines B.V., Leiden, the Netherlands Angiochem Inc....
BioCentury | Dec 7, 2015
Clinical News

ANG1005: Interim Phase II data

...generally well tolerated. Data were presented at the Society for Neuro-Oncology meeting in San Antonio. Angiochem...
...Phase III program of ANG1005 to treat breast cancer patients with or without leptomeningeal carcinomatosis. Angiochem Inc....
BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: Epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2; neu)

...steps could include testing ANG4043 additional rodent brain tumor models and assessing its safety profile. Angiochem Inc....
...Cancer Ther.; published online Dec. 9, 2014; doi:10.1158/1535-7163.MCT-14-0399 CONTACT: Jean Lachowicz, Angiochem Inc., Montreal, Quebec e-mail: jlachowicz@angiochem.com BC...
BioCentury | Dec 15, 2014
Clinical News

Angiochem preclinical data

...Molecular Cancer Therapeutics. ANG4043 consists of the Angiopep-2 peptide conjugated to an anti- HER2 mAb. Angiochem Inc....
BioCentury | Jun 16, 2014
Regulation

Signal crossing

...It is in Phase I/II testing to treat MPS-VII (Sly syndrome). Companies and Institutions Mentioned Angiochem Inc....
...with iduronidase to treat MPS-I; and AGT-182 , an antibody-fusion with iduronate-2-sulfatase to treat MPS-II. Angiochem Inc....
...LRP1 ( CD91 ), a receptor that ferries biomolecules from the blood to the brain. Angiochem...
BioCentury | Jun 9, 2014
Clinical News

ANG1005: Phase II started

...breast cancer showed that ANG1005 produced no confirmed intracranial responses, the primary endpoint. Last year, Angiochem...
...of stable disease (see BioCentury, Dec. 13, 2010; Dec. 10, 2012 & Oct. 28, 2013). Angiochem Inc....
BioCentury | Mar 13, 2014
Distillery Therapeutics

Indication: Neurology

...delivery of NTS alone or vehicle control. Next steps include IND-enabling studies and clinical testing. Angiochem Inc.'s...
...treat pain. SciBX 7(10); doi:10.1038/scibx.2014.289 Published online March 13, 2014 Angiopep and conjugates patented by Angiochem...
Items per page:
1 - 10 of 57